Prostate Cancer Reports
54

Volume 5 Issue 4
April 2017



Home > Prostate Cancer Reports > Volume 5, Year 2017 > Number 4, April


CONTENTS



DIAGNOSIS AND EVALUATION
ETIOLOGY, PATHOGENESIS AND PATHOLOGY
FOLLOW-UP AND QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS AND OUTCOMES
TREATMENT





DIAGNOSIS AND EVALUATION



PDQ Screening and Prevention Editorial Board.
Prostate Cancer Screening (PDQ®): Health Professional Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2017 Feb 15.
Source | Abstract | Full text | Similar articles




PDQ Screening and Prevention Editorial Board.
Prostate Cancer Screening (PDQ®): Patient Version.
PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2017 Feb 17.
Source | Abstract | Full text | Similar articles




Venderink W, van Luijtelaar A, Bomers JG, van der Leest M, Hulsbergen-van de Kaa C, Barentsz JO, Sedelaar JP, Fütterer JJ.
Results of Targeted Biopsy in Men with Magnetic Resonance Imaging Lesions Classified Equivocal, Likely or Highly Likely to Be Clinically Significant Prostate Cancer.
Eur Urol. 2017 Feb 28. pii: S0302-2838(17)30110-0. doi: 10.1016/j.eururo.2017.02.021. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zattoni F, Agostini E, Cattaneo F, Maruzzo M, Basso U, Zattoni F, Evangelista L.
Fluorocholine PET/CT predicts skeletal progression, skeletal event and cancer specific survival in patients with biochemical relapse for prostate cancer.
Clin Imaging. 2017 Feb 24;43:110-116. doi: 10.1016/j.clinimag.2017.02.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





ETIOLOGY, PATHOGENESIS AND PATHOLOGY



Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, Paone A.
Glucose Metabolism in the Progression of Prostate Cancer.
Front Physiol. 2017 Feb 21;8:97. doi: 10.3389/fphys.2017.00097. eCollection
Source | Abstract | Full text | Similar articles




Ji G, Huang C, Song G, Xiong G, Fang D, Wang H, Hao H, Cai L, He Q, He Z, Zhou L.
Are the Pathological Characteristics of Prostate Cancer More Aggressive or More Indolent Depending upon the Patient Age?
Biomed Res Int. 2017;2017:1438027. doi: 10.1155/2017/1438027. Epub 2017 Feb 7.
Source | Abstract | Full text | Similar articles





FOLLOW-UP AND QUALITY OF LIFE



Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Khera M.
Sexual Rehabilitation After Treatment for Prostate Cancer-Part 1: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
J Sex Med. 2017 Mar;14(3):285-296. doi: 10.1016/j.jsxm.2016.11.325.
Source | Abstract | Full text | Similar articles




Salonia A, Adaikan G, Buvat J, Carrier S, El-Meliegy A, Hatzimouratidis K, McCullough A, Morgentaler A, Torres LO, Khera M.
Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).
J Sex Med. 2017 Mar;14(3):297-315. doi: 10.1016/j.jsxm.2016.11.324.
Source | Abstract | Full text | Similar articles




Spratt DE.
To ProtecT Our Patients With Prostate Cancer.
JAMA Oncol. 2017 Mar 16. doi: 10.1001/jamaoncol.2017.0274. [Epub ahead of print]
Source | Abstract | Full text | Similar articles





INTEGRATIVE MEDICINE



Rayaprolu SJ, Hettiarachchy NS, Horax R, Phillips GK, Mahendran M, Chen P.
Soybean peptide fractions inhibit human blood, breast and prostate cancer cell proliferation.
J Food Sci Technol. 2017 Jan;54(1):38-44. doi: 10.1007/s13197-016-2426-2. Epub 2017 Jan 13.
Source | Abstract | Full text | Similar articles





OVERALL MANAGEMENT



Grozescu T, Popa F.
Prostate cancer between prognosis and adequate/proper therapy.
J Med Life. 2017 Jan-Mar;10(1):5-12.
Source | Abstract | Full text | Similar articles




Mohler JL, Antonarakis ES, Armstrong AJ, Bahnson RR, Clark C, D'Amico AV, Davis BJ, Eastham JA, Ellis R, Enke CA, Farrington TA, Higano CS, Horwitz EM, Hurwitz M, Kane CJ, Kuettel M, Lang JM, Lee RJ, Penson DF, Plimack ER, Pow-Sang JM, Raben D, Richey S, Roach M 3rd, Rosenfeld S, Schaeffer E, Skolarus TA, Small EJ, Sonpavde G, Srinivas S, Strope SA, Tward J, Twardowski P.
Prostate Cancer, Version 2.2017.
Natl Compr Canc Netw. 2017 Feb 21.
Source | Abstract | Full text | Similar articles





PROGNOSIS AND OUTCOMES



Dahm P, Ilic D, Wilt T.
Similar prostate cancer and all-cause mortality in men with localised prostate cancer undergoing surgery or radiation therapy versus active monitoring at 10 years of follow-up.
Evid Based Med. 2017 Mar 3. pii: ebmed-2016-110634. doi: 10.1136/ebmed-2016-110634. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Milonas D, Venclovas Z, Gudinaviciene I, Zviniene K, Matjosaitis AJ.
Long-Term Oncological Outcomes for Young Men Undergoing Radical Prostatectomy for Localized Prostate Cancer.
Biomed Res Int. 2017;2017:9858923. doi: 10.1155/2017/9858923. Epub 2017 Feb 19.
Source | Abstract | Full text | Similar articles




Santok GD, Abdel Raheem A, Kim LH, Chang K, Lum TG, Chung BH, Choi YD, Rha KH.
Prostate-specific antigen 10-20 ng/mL: A predictor of degree of upgrading to ≥8 among patients with biopsy Gleason score 6.
Investig Clin Urol. 2017 Mar;58(2):90-97. doi: 10.4111/icu.2017.58.2.90. Epub 2017 Feb 15.
Source | Abstract | Full text | Similar articles





TREATMENT



Dong Y, Ruth KJ, Churilla TM, Viterbo R, Sobczak ML, Smaldone MC, Chen DY, Uzzo RG, Hallman MH, Horwitz EM.
The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Can J Urol. 2017 Feb;24(1):8656-8662.
Source | Abstract | Full text | Similar articles | Meeting abstract (2015)




Klotz L.
Active surveillance for low-risk prostate cancer.
Curr Opin Urol. 2017 Mar 4. doi: 10.1097/MOU.0000000000000393.
Source | Abstract | Full text | Similar articles




Saad F.
Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy.
J Clin Oncol. 2017 Mar 13:JCO2017722793. doi: 10.1200/JCO.2017.72.2793. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Showalter TN.
Commentary: In search of answers regarding the benefits and harms of short term ADT for intermediate-risk prostate cancer.
Can J Urol. 2017 Feb;24(1):8663.
Source | Abstract | Full text | Similar articles